Non-Regulatory

December 9, 2011

First-in-Human Whole-Body HER2-Receptor Mapping Using Affibody Molecular Imaging with ABY-025

Solna, Sweden, December 9, 2011. Affibody is pleased to announce that clinical imaging data using anti-HER2 Affibody® molecules have been presented at the 34th San Antonio Breast Cancer Symposium...

Read more

Non-Regulatory

October 26, 2011

Interim Report – January to September 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more

Non-Regulatory

September 19, 2011

Affibody appoints Dr. Fredrik Frejd as VP Research

Stockholm, September 19, 2011. Affibody AB announced today that Ass. Prof. Fredrik Frejd has been appointed to VP Research. Dr. Frejd has worked at Affibody AB since 2002, most...

Read more

Non-Regulatory

September 9, 2011

Affibody AB and GE Healthcare Expands its Relationship in the Field of Large-scale Affinity Purification

STOCKHOLM, Sweden, September 9, 2011 - Affibody AB and GE Healthcare, a division of the General Electric Company, has today expanded its relationship in the field of large-scale affinity...

Read more

Non-Regulatory

August 9, 2011

Interim Report – January to June 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more

Non-Regulatory

May 5, 2011

Interim Report – January to March 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more

Non-Regulatory

May 4, 2011

Algeta ASA obtains licenses to develop cancer therapeutics based on Affibody® technology for two oncology targets

Stockholm May 4, 2011. Affibody AB today signed a license and collaboration agreement with Algeta ASA (OSE: ALGETA) with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on...

Read more

Non-Regulatory

March 3, 2011

Year-End Report 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique...

Read more

Non-Regulatory

October 26, 2010

Interim Report – January to September 2010

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique...

Read more